Torsdag 26 December | 23:57:12 Europe / Stockholm

Kalender

Tid*
2026-01-10 N/A Årsstämma
2025-11-30 N/A Bokslutskommuniké 2025
2025-07-17 08:30 Kvartalsrapport 2025-Q3
2025-04-17 08:30 Kvartalsrapport 2025-Q2
2025-02-19 08:30 Kvartalsrapport 2025-Q1
2025-02-03 N/A X-dag ordinarie utdelning CSMED 0.00 DKK
2025-01-31 N/A Årsstämma
2024-11-30 - Bokslutskommuniké 2024
2024-11-12 - Extra Bolagsstämma 2024
2024-08-15 - Kvartalsrapport 2024-Q3
2024-05-30 - Årsstämma
2024-05-17 - Kvartalsrapport 2024-Q2
2024-03-01 - X-dag ordinarie utdelning CSMED 0.00 DKK
2024-02-14 - Bokslutskommuniké 2023
2024-02-14 - Kvartalsrapport 2024-Q1
2023-12-15 - X-dag ordinarie utdelning CSMED 0.00 DKK
2023-07-18 - Kvartalsrapport 2023-Q3
2023-05-17 - Kvartalsrapport 2023-Q2
2023-04-14 - Extra Bolagsstämma 2023
2023-02-17 - Kvartalsrapport 2023-Q1
2023-02-14 - Årsstämma
2023-02-10 - X-dag ordinarie utdelning CSMED 0.00 DKK
2022-11-18 - Bokslutskommuniké 2022
2022-08-13 - Kvartalsrapport 2022-Q3
2022-05-20 - Kvartalsrapport 2022-Q2
2022-02-18 - Kvartalsrapport 2022-Q1
2021-12-10 - X-dag ordinarie utdelning CSMED 0.00 DKK
2021-12-09 - Årsstämma
2021-11-18 - Bokslutskommuniké 2021

Beskrivning

LandDanmark
ListaSpotlight DK
SektorHälsovård
IndustriLäkemedel & Handel
CS Medica är ett danskt medicintekniskt bolag, dedikerat till läkemedelsforskning, utveckling, tillverkning och global kommersialisering. Bolaget blandar vetenskap och natur för att förbättra patienters liv med cannabinoidterapier för smärtlindring, och för att hantera autoimmuna och stressrelaterade symtom. Globalt erbjuder CS Medica CBD-behandlingar över disk (OTC), inklusive patenterade medicinska produkter, MHRA och MDR-registrerade artiklar, under varumärket CANNASEN® eller med egen märkning.
2024-06-12 15:09:56

CS MEDICA Signs with OneMed for Enhanced Distribution and Marketing in Denmark

CS MEDICA is happy to announce a new strategic partnership with OneMed, a leading distributor in the healthcare sector. This collaboration marks a significant step in CS MEDICA's newly adopted B2B2C strategy, which focuses on generating strategic partnerships for enhanced market access while continuing to prioritize its core values in research and development, production, compliance, and insights.

As part of the Asker Group, OneMed brings a robust distribution network and a deep understanding of the medical device landscape in Northern Europe. This partnership leverages OneMed's extensive expertise and aligns with its vision of improving individuals' health through effective healthcare solutions.
 

Extended Market Reach and Professional Expertise
With this partnership, CS MEDICA aims to utilize OneMed's established channels and professional team to enhance the accessibility of its products in Denmark. This is the initial step in a potential expansion into other markets, reflecting a joint commitment to growth and excellence in healthcare provision.

Launch of New Branding and Packaging
With this partnership, CS MEDICA will launch new product packaging and brand content this October based on feedback from consumers and health professionals. These additions will further diversify our unique portfolio and address the evolving needs of the healthcare industry.

Seamless Transition for Existing Customers
OneMed will take over the distribution and marketing in Denmark from CS MEDICA's subsidiary CANNORDIC, ensuring existing customers receive the high-quality service and products they expect. The aim is to make this transition as smooth as possible for all parties involved, additionally ensuring an uplift in service with the power of OneMed.

"This partnership with OneMed represents a pivotal development in our strategy to expand access and deliver innovative solutions to the healthcare market while being able to focus on our core DNA as a MedTech. We are confident that OneMed's expertise and network will help us reach more patients than we can," says Lone Henriksen, CEO of CS MEDICA.

"We chose CS MEDICA as our partner because they have successfully positioned themselves as leaders in compliant medical devices with CBD, which perfectly matches current market trends and regulations. Their proactive transition to MDR with a Notified Body sets them ahead of the competition, aligning perfectly with our mission to support superior health outcomes," says Henning Rune Carlsen, Sales & Category Director of OneMed.